Business
Marina Biotech Receives Milestone Payment From SMARTICLES Licensee MiNA Therapeutics
Marina Biotech Receives Milestone Payment From SMARTICLES Licensee MiNA Therapeutics.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech Receives Milestone Payment From SMARTICLES Licensee MiNA Therapeutics\n \n \nMarina Biotech Receives Milestone Payment From SMARTICLES Licensee MiNA Therapeutics\n \n BOTHELL, WA--(Marketwired - Nov 17, 2015) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that it received a milestone payment, in the amount of $200,000, from its licensee, MiNA Therapeutics Limited (MiNA), a privately-held biotechnology company pioneering short activating RNA (saRNA) as therapeutic agents for the treatment of human diseases. \n \"We are extremely pleased with MiNA's progress as the forerunner in the development of saRNA-based therapeutics,\" stated J. Michael French, President and CEO of Marina Biotech. \"Further, I believe the rapid advancement of their technology continues to demonstrate the versatility of SMARTICLES for the safe and effective delivery of nucleic acid compounds. We look forward to the continued progress of the MiNA team and to the treatment options that their novel approach can bring to patients in need.\" \n About Marina Biotech, Inc.\n Marina Biotech is an oligonucleotide therapeutics company with broad drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. These technologies were built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little thereby causing a particular disease. We believe that the Marina Biotech technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. Further, we believe Marina Biotech is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, M...